HALOZYME THERAPEUTICS, INC. STOCK OPTION AGREEMENTStock Option Agreement • November 9th, 2015 • Halozyme Therapeutics Inc • Biological products, (no disgnostic substances) • Delaware
Halozyme Therapeutics, Inc. has granted to the Participant named in the Notice of Grant of Stock Option (the “Grant Notice”) to which this Stock Option Agreement (the “Option Agreement”) is attached an option (the “Option”) to purchase certain shares of Stock upon the terms and conditions set forth in the Grant Notice and this Option Agreement. The Option has been granted pursuant to and shall in all respects be subject to the terms and conditions of the Halozyme Therapeutics, Inc. 2011 Stock Plan (the “Plan”), as amended to the Date of Grant, the provisions of which are incorporated herein by reference. By signing the Grant Notice, the Participant: (a) acknowledges receipt of and represents that the Participant has read and is familiar with the Grant Notice, this Option Agreement, the Plan and a prospectus for the Plan in the form most recently registered with the Securities and Exchange Commission (the “Plan Prospectus”), (b) accepts the Option subject to all of the terms and conditi
HALOZYME THERAPEUTICS, INC. RESTRICTED STOCK UNITS AGREEMENT UNDER THE HALOZYME THERAPEUTICS, INC. 2011 STOCK PLANRestricted Stock Units Agreement • November 9th, 2015 • Halozyme Therapeutics Inc • Biological products, (no disgnostic substances) • Delaware
HALOZYME THERAPEUTICS, INC. RESTRICTED STOCK AWARD AGREEMENT UNDER THE HALOZYME THERAPEUTICS, INC. 2011 STOCK PLANRestricted Stock Award Agreement • November 9th, 2015 • Halozyme Therapeutics Inc • Biological products, (no disgnostic substances) • Delaware
AMENDED AND RESTATED CHANGE IN CONTROL AGREEMENTChange in Control Agreement • November 9th, 2015 • Halozyme Therapeutics Inc • Biological products, (no disgnostic substances) • California
This Amended and Restated Change in Control Agreement (this “Agreement”) is dated [DATE], and is by and between HALOZYME THERAPEUTICS, INC., a Delaware corporation (the “Company,” “us,” “we” or “our”), and [EXECUTIVE NAME] (“you” or “your”).
